Targeting the Wnt/beta-catenin pathway in multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The Wnt signaling pathway is constitutively activated in multiple myeloma (MM), driving excessive cell proliferation.
• Targeting the Wnt pathway presents a promising therapeutic strategy for MM treatment.

Purpose of the Study:

• To investigate the effects of combining ethacrynic acid (EA) and ciclopirox olamine (CIC) with piceatannol (PIC) on Wnt pathway activity and myeloma cell viability.
• To assess the impact of these combinations on both human and murine myeloma cell lines.

Main Methods:

• Utilized DiOC6 and propidium iodide (PI) staining with flow cytometry to analyze cell viability.
• Employed immunoblotting to examine changes in Wnt pathway components, including beta-catenin and its downstream factors.

Main Results:

• Combined EA with PIC, and CIC with PIC, demonstrated a significant additive effect on reducing myeloma cell vitality compared to single agents.
• Healthy cells remained largely unaffected by the combined treatments.
• EA and CIC treatments altered the expression of beta-catenin and its downstream signaling molecules.

Conclusions:

• Combination therapy using Wnt inhibitors shows potential for novel treatment strategies in multiple myeloma.
• Targeting the Wnt pathway with combined agents like EA, CIC, and PIC could offer new therapeutic avenues for MM patients.